Terminated PHASE3 INTERVENTIONAL 2-arm NCT00589693

To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia

A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects With Ventilator-Associated Pneumonia

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions Ventilator-Associated Pneumonia

Interventions Doripenem Imipenem-Cilastatin Placebo

Updated 8 times since 2017 Last updated: Dec 24, 2012 Started: Apr 30, 2008 Primary completion: Jun 30, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Observed lower cure rates and higher mortality rates in one of the treatment groups.

Other terminated trials from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More terminations from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

A PHASE3 clinical study on Ventilator-Associated Pneumonia, this trial is terminated or withdrawn. The trial is conducted by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Adelaide, Australia , Afula, Israel , Ankara, Turkey (Türkiye) , Argenteuil, France , Baltimore, United States , Bangalore, India , Barcelona, Spain , Belo Horizonte, Brazil , Biddeford, United States and 90 more locations